

# Contents

List of Figures.....	v-vii
List of Tables.....	viii-x
List of Abbreviations.....	xi-xiii
<b>1. Introduction.....</b>	<b>1-17</b>
<b>2. Aim and Objectives.....</b>	<b>18-20</b>
<b>3. Review of Related Literature.....</b>	<b>21-61</b>
<b>4. Experimental set up.....</b>	<b>62-65</b>
<b>5. Development of Compression-coated Pulsatile Release (PR) formulations.....</b>	<b>66-226</b>
5.1. Quality by Design (QbD) enabled development of PR Compression-coated tablets (CCTs) of Prednisone (PRS).....	66
5.1.1. PRS drug profile.....	66
5.1.2. Methods (PRS).....	70
5.1.2.1. Analytical method for determination of PRS.....	70
5.1.2.2. Establishment of Quality Target Product Profile (QTPP).....	78
5.1.2.3. Identification of Critical Quality Attributes (CQAs) and their Risk assessment.....	80
5.1.2.4. Risk assessment by Failure Mode and Effects Analysis (FMEA).....	80
5.1.2.5. Drug-excipient compatibility.....	81
5.1.2.6. Preparation of PRS core tablets.....	81
5.1.2.7. Characterization of PRS core tablets.....	82
5.1.2.8. Preparation of PRS CCTs.....	83
5.1.2.9. Characterization of PRS CCTs.....	84
5.1.2.10. Packaging and stability study (PRS CCTs).....	85
5.1.3. Results and discussion (PRS).....	86
5.1.3.1. QTPP.....	86
5.1.3.2. Identification of CQAs and their risk assessment.....	86
5.1.3.3. Evaluation of PRS core tablets.....	97
5.1.3.4. Evaluation of PRS CCTs.....	98
5.1.3.4.1. Selection of lubricant and glidant.....	98
5.1.3.4.2. Selection of hydrophilic additive.....	108
5.1.3.4.3. Selection of HPMC MW grade.....	110
5.1.3.4.4. Risk assessment by FMEA.....	123
5.1.3.4.4.1. Risk assessment of core elements.....	125

5.1.3.4.4.2. Risk assessment of coating elements.....	125
5.1.3.4.4.3. Statistical optimization.....	126
5.1.3.4.4.4. Evaluation of optimized PRS CCTs.....	132
5.1.3.4.4.5. Updated risk assessment.....	137
5.1.4. Conclusion (PRS).....	143
5.2. Development of PR CCTs of Methylprednisolone (MPR).....	145
5.2.1. MPR drug profile.....	145
5.2.2. Methods (MPR).....	147
5.2.2.1. RP-HPLC method for determination of MPR.....	147
5.2.2.2. Drug-excipient compatibility.....	150
5.2.2.3. Preparation of MPR core tablets.....	150
5.2.2.4. Characterization of MPR core tablets.....	151
5.2.2.5. Preparation of MPR CCTs.....	151
5.2.2.6. Characterization of MPR CCTs.....	151
5.2.2.7. Packaging and stability study (MPR CCTs).....	151
5.2.3. Results and discussion (MPR).....	152
5.2.3.1. Evaluation of MPR core tablets.....	152
5.2.3.2. Evaluation of MPR CCTs.....	153
5.2.4. Conclusion (MPR).....	155
5.3. Development of PR CCTs of Diclofenac sodium (DIC).....	156
5.3.1. DIC drug profile.....	156
5.3.2. Methods (DIC).....	158
5.3.2.1. RP-HPLC method for determination of DIC.....	158
5.3.2.2. Drug-excipient compatibility.....	161
5.3.2.3. Preparation of Active Pharmaceutical Ingredient (API) granules of DIC ..	161
5.3.2.4. Preparation of DIC core tablets.....	161
5.3.2.5. Characterization of DIC core tablets.....	162
5.3.2.6. Preparation of DIC CCTs.....	162
5.3.2.7. Characterization of DIC CCTs.....	162
5.3.2.8. Packaging and stability study (DIC CCTs) .....	162
5.3.3. Results and discussion (DIC).....	163
5.3.3.1. Flow property evaluation of DIC compression blends.....	163
5.3.3.2. Evaluation of DIC core tablets.....	163
5.3.3.3. Evaluation of DIC CCTs.....	164

5.3.4. Conclusion (DIC).....	167
5.4. Development of PR CCTs of Diltiazem hydrochloride (DIL).....	168
5.4.1. DIL drug profile.....	168
5.4.2. Methods (DIL).....	170
5.4.2.1. RP-HPLC method for determination of DIL.....	170
5.4.2.2. Drug-excipient compatibility.....	173
5.4.2.3. Preparation of API granules of DIL.....	173
5.4.2.4. Preparation of DIL core tablets.....	173
5.4.2.5. Characterization of DIL core tablets.....	174
5.4.2.6. Preparation of DIL CCTs.....	174
5.4.2.7. Characterization of DIL CCTs.....	174
5.4.2.8. Packaging and stability study (DIL CCTs).....	174
5.4.3. Results and discussion (DIL).....	175
5.4.3.1. Flow property evaluation of DIL compression blend.....	175
5.4.3.2. Evaluation of DIL core tablets.....	175
5.4.3.3. Evaluation of DIL CCTs.....	176
5.4.4. Conclusion (DIL).....	179
5.5. Development of PR CCTs of Nifedipine (NIF).....	180
5.5.1. NIF drug profile.....	180
5.5.2. Methods (NIF).....	183
5.5.2.1. RP-HPLC method for determination of NIF.....	183
5.5.2.2. Drug-excipient compatibility.....	186
5.5.2.3. Preparation of NIF amorphous solid dispersion (ASD).....	186
5.5.2.4. Characterization of NIF ASD.....	186
5.5.2.5. Preparation of NIF core tablets.....	187
5.5.2.6. Characterization of NIF core tablets.....	187
5.5.2.7. Preparation of NIF CCTs.....	188
5.5.2.8. Characterization of NIF CCTs.....	188
5.5.2.9. Packaging and stability study (NIF CCTs).....	188
5.5.3. Results and discussion (NIF).....	189
5.5.3.1. Evaluation of NIF ASD.....	189
5.5.3.2. Evaluation of NIF core tablets.....	194
5.5.3.3. Evaluation of NIF CCTs.....	195
5.5.4. Conclusion (NIF).....	197

5.6. Development of PR CCTs of Lornoxicam (LOR).....	198
5.6.1. LOR drug profile.....	198
5.6.2. Methods (LOR).....	200
5.6.2.1. RP-HPLC method for determination of LOR.....	200
5.6.2.2. Drug-excipient compatibility.....	203
5.6.2.3. Preparation of LOR ASD.....	203
5.6.2.4. Characterization of LOR ASD.....	203
5.6.2.5. Preparation of LOR core tablets.....	204
5.6.2.6. Characterization of LOR core tablets.....	204
5.6.2.7. Preparation of LOR CCTs.....	204
5.6.2.8. Characterization of LOR CCTs.....	204
5.6.2.9. Packaging and stability study (LOR CCTs).....	204
5.6.3. Results and discussion (LOR).....	205
5.6.3.1. Evaluation of LOR ASD.....	205
5.6.3.2. Evaluation of LOR core tablets.....	209
5.6.3.3. Evaluation of LOR CCTs.....	210
5.6.4. Conclusion (LOR).....	212
5.7. Developed compression-coated PR formulation - A platform technology.....	213
<b>6. Development of Pan-coated PR formulations.....</b>	<b>227-244</b>
6.1. Methods.....	227
6.1.1. Analytical methods for determination of drugs.....	227
6.1.2. Preparation and characterization of core tablets.....	227
6.1.3. Preparation of pan-coated tablets (PCTs).....	227
6.1.4. Characterization of PCTs.....	228
6.1.5. Packaging and stability study.....	228
6.1.6. <i>In vivo</i> pharmacokinetic study of DIC PCT formulation.....	229
6.1.6.1. Quantification of DIC in rabbit plasma using LC-MS method.....	229
6.2. Results and discussion.....	233
6.2.1. Evaluation of PCTs.....	233
6.2.2. Packaging and stability.....	238
6.2.3. <i>In vivo</i> pharmacokinetic study of DIC PCT formulation.....	239
6.3. Conclusion.....	241
<b>7. Summary and Conclusion.....</b>	<b>245-253</b>
<b>Publications.....</b>	<b>254</b>